Propranolol Oral Treatment for Infantile Hemangioma : A Systematic Review

Aulia Nissa Rizky Hariyono, Ratih Pramuningtyas, Zhela Fatin Fatiha, Ayu Mayangsari, Tia Mella Citra

Abstract


The most common benign tumor in infants is infantile hemangioma. Propranolol is often used as a treatment in patients with IHs. Efficacy and side effects of oral propranolol are considered important to be systematically reviewed in the management of IH. We searched Google Scholar, Pubmed, Garuda, and Science Direct. The articles matched with the restriction criteria then screened using the PRISMA method. The quality of the articles is tested using GRADE method. Total of 4 of 6289 articles recorded at the identification stage according to the inclusion criteria, 452 patients were treated with oral propranolol. All four articles were randomized clinical trials. Treatment is given at 0.3 month to 15 years of age, the dose given is 1-3 mg/kg/day. The primary end point was performed at week 24. The most common side effect is sleeping disorder (n=85). Serious side effects (Hypotension, bronchospasm, bradycardia, hypoglycemia) were managed by decreasing doses or temporary/permanent discontinuation of oral propranolol. Oral propranolol can be used with good efficacy. Monitor before and during treatment is assessed appropriately to reduce side effect.


Keywords


adrenergic antagonist; propranolol; infantile hemangioma

Full Text:

PDF

References


Akobeng, A. K., 2005. Principles of Evidence Based Medicine. Archives of disease in childhood , 90(8), pp. 837-840.

Amal Chamli, P. A. R. T. J. N. L., 2019. Hemangioma. StatPearls Publishing, Treasure Island (FL).

Anita Rotter, Z. N. P. d. O., 2017. Infantile hemangioma: pathogenesis and mechanisms of action of propranolol. J Dtsch Dermatol Ges, 15(12), pp. 1185-1190.

Antony George, V. M. a. A. N., 2014. Update on The Classification of Hemangioma. Journal of Oral and Maxillofacial Pathology, 18(Suppl 1), p. S117.

Arin K. Greene, M. M., 2011. Management of Hemangiomas and Other Vascular Tumors. Plasticsurgery.theclinics.com, 38(1), pp. 45-63.

Aziz Eghbali, S. H. B. S. S. A. P. V. M. a. B. B., 2017. A 24-Week Treatment of Pediatric Hemangioma with Oral Propranolol. Iran J Pharm Res, 16(2), pp. 811-816.

Christine Léauté-Labrèze, M. P. H. M. J. M.-H. M. L. G. M., 2015. A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma. N Engl J Med, pp. 735-746.

Daniel P. Krowchuk, M. F. I. J. F. M. F. A. J. M. M. F., 2019. Clinical Practice Guideline for the. American Academy of Pediatrics, 143(1).

David Moher, A. L. T. G. A. P. G., 2009. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS medicine, 6(7), p. e1000097.

Jailani, M. (2020). Hemangioma of Lower Lip - A Case Report. Budapest International Research in Exact Sciences (BirEx) Journal. P. 410-417.

Kyu Han Kim, M. P., Tae Hyun Choi, M. P., Yunhee Choi, P. & al, e., 2017. Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: a randomized clinical trial. JAMA dermatology, pp. 529-536.

Maguiness SM, F. I., 2010. Current management of infantile hemangiomas. Seminars in cutaneous medicine and surgery, 29(2), pp. 106-114.

Marcia Hogeling, S. A. a. O. W., 2011. A Randomized Controlled Trial of Propranolol for Infantile Hemangiomas. Pediatrics, 128(2), pp. e259-e266.

Mohammed Muneeb Mubashir, A. K. N. O. N. G., 2018. A Case Report on Infantile Hemangioma. International Journal of Health Sciences and Research, 8(11), pp. 322-323.

Neurol, A. I. A., 2019. Propranolol: A 50-Year Historical Perspective. Annals of Indian Academy of Neurology, 22(1), pp. 21-26.

Sangy, S., et al. (2021). Study of Thymus and T- cell Development and Tumor Immunology. Budapest International Research in Exact Sciences (BirEx) Journal. P. 162-170.

Staff, M. C., 2021. Hemangioma. [Online] Available at: https://www.mayoclinic.org/diseases-conditions/hemangioma/symptoms-causes/syc-20352334?p=1 [Accessed 15 July 2021].

Van An Nguyen, H. K. C. F. A. T. &. N. S., 2006. Infantile hemangioma is a proliferation of LYVE-1-negative blood endothelial cells without lymphatic competence. Modern Pathology, 19(2), p. 291–298.




DOI: https://doi.org/10.33258/birci.v4i3.2308

Article Metrics

Abstract view : 71 times
PDF - 19 times

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.